DUXAP8 and hepatocellular carcinoma: The upregulation of the pseudogene-derived lncRNA DUXAP8 has been linked to HCC progression and reduced sorafenib efficacy, principally through DUXAP8’s modulation of MAPK1 via miR-584–5p, thus activating the MAPK/ERK pathway (Liu et al., 2021).